Register Log-in Investor Type

Events

FT Global Pharmaceutical and Biotechnology Conference

Description

The global life sciences industry is facing a level of disruption unprecedented in its long history. Once considered the holy grail of medicine, a new generation of gene-based therapies is dawning at last, holding out the promise of a paradigm shift from treatment to care, but also challenging our healthcare systems’ ability to afford the new age of biology.  China, meanwhile, is rising as a force to be reckoned with, both in terms of its potential for drug development, as well as in its ready embrace of digital technologies to transform R&D, health treatment and services.

The Financial Times Annual FT Global Pharmaceutical and Biotechnology Conference, now in its 36th successful year brings together the industry’s top executives and visionaries to explore the latest trends from biosimilars, to digital therapeutics to next generation neuroscience and diagnostics set to reshape the industry far into the future.

Speakers

Joanne Waldstreicher

Joanne Waldstreicher, M.D., is Chief Medical Officer, Johnson & Johnson. In this role, she has oversight across pharmaceuticals, devices and consumer products for safety, epidemiology, clinical and regulatory operations transformation, collaborations on ethical science, and technology and R& D policies, including those related to trial transparency and compassionate access. She Chairs the R&D development pipeline review committee for Janssen, the pharmaceuticals group of Johnson & Johnson, and supports Device and Consumer Development committees. Dr Waldstreicher is also a Faculty Affiliate of the Division of Medical Ethics, Department of Population Health, New York University School of Medicine. Among her prior roles, she was responsible for late-stage development in neuroscience, cardiovascular disease and metabolism at Janssen. Before joining Johnson & Johnson in 2002, Dr Waldstreicher headed Endocrinology and Metabolism clinical research at Merck Research Laboratories, overseeing development programs in atherosclerosis, obesity, diabetes, urology and dermatology. She was honoured with the Key Innovator Award, among other distinctions. Dr Waldstreicher, received both the Jonas Salk and Belle Zeller scholarships from the City University of New York, and graduated Summa Cum Laude from Brooklyn College. She graduated Cum Laude from Harvard Medical School, completed her internship and residency at Beth Israel Hospital, and her endocrinology fellowship at Massachusetts General Hospital. She has received numerous awards and scholarships, and is an active scientific author. In 2016, the National Association of Female Executives named her Healthcare Champion of the Year.

Katrine Bosley

Katrine Bosley is the Chief Executive Officer of Editas Medicine. Prior to joining Editas, Ms Bosley was an Entrepreneur-in-Residence at The Broad Institute, a biomedical and genomic research center, and before that, she was the CEO of Avila Therapeutics (acquired by Celgene). She was also Vice President, Business Development at Adnexus Therapeutics and then Vice President, Strategic Operations after Adnexus’ acquisition by Bristol-Myers Squibb. Earlier, Ms Bosley held several positions at Biogen in Business Development, Commercial Operations, and Portfolio Strategy and was part of the healthcare team at the venture firm Highland Capital Partners.

In addition to her role at Editas, Ms Bosley currently serves as Chairman of the Board of Genocea Biosciences (NASDAQ: GNCA) and is a member of the Board of Directors of Galapagos NV (EURONEXT and NASDAQ: GLPG), of BIO – the Biotechnology Innovation Organization, and of Massachusetts Eye and Ear.

Ms Bosley is a graduate of Cornell University

Mene Pangalos

Mene Pangalos is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit and Global Business Development. A member of the company’s Senior Executive Team, Dr Pangalos has overall responsibility for AstraZeneca’s research and early development activities spanning three continents and 2,500 people.

Since joining AstraZeneca in 2010, Dr Pangalos has led a transformation of its R&D productivity resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration.

One of AstraZeneca’s leading scientists, Dr Pangalos has published over 150 peer-reviewed articles in scientific journals and has served as editor of various books and journals. He is a Visiting Professor of Neuroscience at King’s College London and the holder of an Honorary degree of Doctor of Science from Glasgow University.

Dr Pangalos makes a significant contribution to UK science. He is a Fellow of the Academy of Medical Sciences, the Royal Society of Biology and Clare Hall, University of Cambridge. He sits on the Medical Research Council (MRC) Council, co-chairs the Life Sciences Council Expert Group on Innovation, Clinical Research and Data and is a member of the Life Sciences Industrial Strategy Implementation Board and National Genomics Board. He is also a Board member of the British Pharmaceutical Group and Cambridge University’s Judge Business School.

Nick Leschly

Chief Bluebird
Bluebird Bio

William Mayo

Chief Information Officer
The Broad Institute-MIT and Harvard

Peter Donnelly

CEO, Professor of Statistical Science
Genomics plc, Wellcome Centre for Human Genetics, University of Oxford

Julie Gerberding

Dr Julie Gerberding is responsible for Merck’s commercial portfolio of vaccines, planning for the introduction of vaccines from the company's pipeline, and accelerating access to vaccines around the world. She also co-chairs the Board of Sanofi Pasteur MSD vaccines (a joint venture in Europe). Dr Gerberding served as Director, US. Centers for Disease Control and Prevention (2002-2009) where she led numerous emergency responses to public health crises, including anthrax bioterrorism, SARS, Ebola, and natural disasters. Dr Gerberding is a passionate advocate for sustainable global health solutions and serves on the Boards of Directors of Project HOPE, Accordia Global Health Foundation and the MSD Wellcome Trust Hilleman Laboratories (India).

Mark Mallon

Mark Mallon was appointed Executive Vice-President (EVP), Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs in August 2016, leading AstraZeneca’s global marketing and commercial portfolio strategy as well as the medical and corporate affairs functions. These functions integrate corporate, therapy area and product strategies to bridge scientific development and commercial excellence in the core areas of cardiovascular and respiratory diseases. Prior to this, Mr Mallon was Executive Vice President for the International region with responsibility for the growth and performance of AstraZeneca’s commercial businesses in various parts of the world, including Asia Pacific, Russia, Latin America, the Middle East and Africa. Since joining AstraZeneca in 1994, Mr Mallon has held many senior sales and marketing roles, including Regional Vice-President for Asia Pacific, President of AstraZeneca’s Chinese and Italian subsidiaries, Chief Operating Officer of AstraZeneca’s Japanese subsidiary and Vice-President of AstraZeneca’s US gastrointestinal and respiratory businesses. Mr Mallon began his career in the pharmaceutical industry in management consulting. He holds a degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business.

Mike Gladstone

Mike Gladstone is the Global President of Internal Medicine at Pfizer Inc., one of the world’s premier innovative biopharmaceutical companies. He is responsible for a $9 billion global portfolio of medicines spanning cardiovascular metabolic and pain therapeutic areas. He oversees approximately 8,000 colleagues, including Pfizer’s Country Managers and Medical Directors who represent the company to external stakeholders globally. Mr Gladstone has over 25 years of experience in the pharmaceutical industry and has held a number of senior global positions across Pfizer.

Prior to this position, Mr Gladstone was the North America Regional President for Internal Medicine. In addition, he was appointed as the US Country Manager for Pfizer. Before this, he was the Chief Marketing Officer for the US Primary Care Business Unit.

Previously, Mr Gladstone spent three years living in Sweden and three years in Italy where he held multiple positions including serving as the European Specialty Care Asset Team Leader for Inflammation and all Specialty Care brands for 16 countries in Europe and as the Managing Director for the Nordic countries.

Earlier in his career, Mr Gladstone advanced through various positions in Sales, Marketing, Healthcare Systems, National Accounts and General Management in the US and eventually became Vice President for Gastroenterology and Metabolic Diseases.

Mr Gladstone serves on the board of the U.S. Healthcare Leadership Council and he retains a seat on the Executive Committee. He is also on the board of the Partnership for America’s Health Care Future and previously was on the board of the National Pharmaceutical Council.

Jane Griffiths

Global Head
Actelion

Stephen Moran

Stephen Moran is Global Head of Strategy for Novartis, a position he has held since January 1, 2017. Dr Moran joined Novartis in January 2015 as Strategic Assistant to the CEO. Prior to that, he was an Associate Principal at McKinsey & Company, serving as a leader in the healthcare practice. There his work focused on health system sustainability, research and development strategy and the economic analysis of clinical interventions across disease pathways. Dr Moran holds a Bachelor of Arts and a Master of Science in Natural Sciences from the University of Cambridge in the United Kingdom, and a doctorate in Biochemistry from the University of Oxford.

Richard Francis

CEO
Sandoz

Christian Hogg

Mr Hogg joined Chi-Med in 2000, as its first employee, and has since led all aspects of the creation, implementation and management of the company’s strategy, business and listings. This includes the establishment of the company’s Innovation Platform, which now comprises eight clinical drug candidates, primarily in oncology, in over 30 clinical studies around the world and a scientific team of over 330 people based in Shanghai. Furthermore, the acquisition and operational integration of assets that led to the formation of the company’s Commercial Platform which manufactures and markets over 200 drugs through a team of over 3,300 marketing personnel covering over 300 cities and towns in China. Prior to joining Chi-Med, Mr Hogg spent ten years with P&G starting in the US in Finance and then Brand Management in the Laundry and Cleaning Products Division. Mr Hogg then moved to China to manage P&G’s detergent business followed by a move to Brussels to run P&G’s global bleach business. Mr Hogg received a Bachelor’s degree in Civil Engineering from the University of Edinburgh and an MBA from the University of Tennessee.

Rehan Verjee

Executive Vice President, Chief Marketing and Strategy Officer
Merck Healthcare

Pamela Cyrus

Vice President and Head Medical Governance, Pharmaceuticals
Bayer

Christopher Boerner

Head of International Markets
Bristol-Myers Squibb

Udit Batra

Member of the Executive Board, CEO Life Science
Merk

Keiron Sparrowhawk

Founder and CSO
MyCognition

Niels Lund

Vice President, Health Advocacy
Novo Nordisk

Dr Hans-Georg Eichler

Hans-Georg Eichler, MD, MSc, is the Senior Medical Officer at the European Medicines Agency (EMA) in the United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years. He was Vice-Rector for Research and International Relations from 2003, and Professor and Chair of the Department of Clinical Pharmacology from 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, UK, and Outcomes Research at Merck & Co, in New Jersey. In 2011, Dr Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative.

Dr Eichler graduated with an MD from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, UK. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Bruno Holthof

CEO
NHS Oxford University Hospitals

Professor Sir John Bell

Professor Sir John Bell is Regius Professor of Medicine at Oxford University and the former President of the Academy of Medical Science. He has been extensively involved in the development of research programmes in genetics and genomics and in the development of clinical research programmes across the UK. Professor Bell was the Founder of the Wellcome Trust Centre for Human Genetics and has led the significant expansion in biomedical research activities in the Clinical School in Oxford since 1992. He is a non-executive director of Roche AG (since 2001) and of Genentech (since 2009). He is also a member of the Bill and Melinda Gates Foundation Scientific Advisory Committee and a Board Member of the UK Clinical Research Collaboration and UK Biobank. Professor Bell is currently the Life Sciences Champion to the UK Prime Minister advising on Life Sciences Strategy.

Deborah Harland

Partner
SR One

Chris Edson

CEO
Our Path

Billy Boyle

Billy Boyle co-founded Owlstone Inc. in Cambridge in 2004. The company develops, manufactures and supplies advanced chemical detection solutions across a wide range of markets and applications and has raised $28M in investment and won over $25M in defence contracts. Mr Boyle initially worked with silicon foundries in the design and fabrication of the core microchip technology and is co-inventor on 19 patents. He then assumed a commercial role with P&L responsibility for the Scientific Instruments and Industrial business units; responsible for sales of FAIMS products and contracts with over 150 clients globally, including Agilent, Thermo, Roche Diagnostics, Samsung, GSK, 4D Pharma, Mayo Clinic and the NHS.Mr Boyle started to focus on the medical applications of FAIMS technology after his wife, was diagnosed and later died of colon cancer as a result of a late diagnosis. He headed up the newly formed Medical business unit, with the ongoing clinical and commercial success, and investment, he spun out Owlstone Medical Ltd in March 2016. Mr Boyle, an engineering graduate from Cambridge University, is a judge for the Cancer Research UK (CRUK) Pioneer award and a Trustee of the Linacre Institute.

Iain Stewart

President
National Research Council Canada

John Reynders

Vice President, R&D Strategy, Program Management & Data Sciences
Alexion Pharmaceuticals

Ali Tehrani

President & CEO
Zymeworks

David Crow

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Sarah Neville

Sarah Neville began her career on local and regional newspapers, eventually becoming political editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. She joined the Financial Times in 2001 and has since held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and public policy editor in 2011. She was appointed Pharmaceuticals Correspondent in 2016.

Greg Reh

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

Jessica Federer

Jessica Federer leads digital development at Bayer, a global enterprise advancing Science For A Better Life in the areas of human, animal and plant health. Recognized as one of the top 100 global CDOs and a leading Health Tech Influencer, Federer is passionate about translating digital developments into meaningful public health advancements. Federer previously held positions in Regulatory Affairs, Market Access, Communications and Public Affairs, and worked at the Agency for Healthcare Research and Quality at the US Department of Health and Human Services.

Jessica serves as a Board Member for the MedicAlert Foundation, the UN Agency for Information and Communications Technology (ITU), the World Economic Forum Digital Transformation of Industries Initiative for Chemistry and Advanced Materials, and the Bayer Cares Foundation Committees for both the Employee Volunteer program and the Aspirin Social Innovation Award.

She received a Master of Public Health degree from the Yale School of Public Health, and a Bachelor of Science from The George Washington University. Originally from St. Louis, Missouri, she now lives in Düsseldorf, Germany.

Ulrich Mühlner

Ulrich Mühlner is a senior healthcare executive with 17 years of industry experience. In 2016, he started GrowthCube Partners and became an active startup investor and entrepreneur to enable life-changing healthcare innovations by joining forces with scientists, innovators, and entrepreneurs, and - together - translating groundbreaking ideas, discoveries, and inventions into services and products that make a real difference to people’s lives. Dr Mühlner is particularly passionate about radically transforming the pharma industry through Big Data, Artificial Intelligence, and Deep Learning. In addition, Dr Mühlner is the CEO, Chairman and Co-Founder of docdok.health Ltd, a recently founded company with the mission to transform the quality, delivery and experience of medical care for both doctors and patients through its innovative cloud-based connected personalised health communication platform. He also serves as the CEO of E-Medicus Ltd. and globally as board member and advisor to biopharma and digital health/health tech companies, as well as international organisations and leading academic institutions. Previously, Dr Mühlner worked at Novartis and The Boston Consulting Group (BCG). At Novartis he served as Director and Head Global Corporate Strategy, Global Head Outcomes Technologies Incubator.In this role, he was responsible for the multi-billion dollar portfolio transformation strategy and spearheaded globally the digital health activities across Novartis leading to major digital health partnerships (Google/Verily, IBM, Proteus) with the aim to increase the value of the Novartis portfolio through ‘beyond-the-drug’ real-world outcomes solutions. In total, Dr Mühlner successfully executed deals with a volume of $350mn. Dr Mühlner studied Biochemistry in Hannover and Munich, and earned a PhD degree in Biochemistry and Molecular Biology based on his research on molecular mechanisms of cancer development at the Research Institute of Molecular Pathology (I.M.P.) in Vienna.

Lisa Anson

President
AstraZeneca UK

Julie Ducharme

Julie Ducharme leads research and development for the Mundipharma network outside the US, guiding a portfolio of medicines through clinical trials to registration and reimbursement.

She joined Mundipharma from Purdue Pharma Canada where she was Vice President, Research and Development. Previously, Dr Ducharme led the research and development of biologics and vaccines as General Manager of Human Health Therapeutics at the National Research Council of Canada (NRC), transforming it into one of NRC’s leading portfolios. Her move to the NRC followed almost 16 years at AstraZeneca in senior leadership roles building and leading cross-functional international teams. Earlier in her career, Julie spent nine years in clinical research in academia and the pharmaceutical industry. Dr Ducharme is also an adjunct Professor of Pharmacy at the Université de Montréal and sits on several scientific advisory boards. She holds a PhD from the University of Montreal, Canada, post-doctorates from Université Paris VI, France and McGill University, Canada.

Virginia Acha

Director, Regulatory Affairs
Amgen

Christina Nesheva

Operations Director, Hive Innovation Unit,
ViiV

Mike Standing

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Richard Mason

Richard Mason is the Head of Johnson & Johnson London Innovation Centre and is responsible for Johnson & Johnson Innovation within the EMEA region. In this role, Dr Mason leads a team of transaction and scientific innovation experts to identify and develop a diverse portfolio of early stage partnerships and investments across all three sectors of Johnson & Johnson. Prior to joining Johnson & Johnson Innovation, he was CEO of XO1 Limited until the company was acquired by Janssen in March 2015. Prior to his role at XO1, Dr Mason was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. Mr Mason also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT). Dr Mason trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree Immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals

Francesco De Rubertis

Francesco De Rubertis is Partner and Co-Founder of Medicxi. Prior to this, he was with Index Ventures for 18 years, having joined the firm in 1997 to launch its life sciences practice. While at Index life sciences, he spearheaded the creation and adoption of an asset-centric investment strategy and led the growth of the firm. At Medicxi he also oversees the firm’s operations. Among Dr De Rubertis’s investments are CellZome (acquired by GlaxoSmithKline), Egalet (NASDAQ: EGLT), GenMab (NASDAQ Copenhagen: GEN), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (NASDAQ: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, NASDAQ: AFFX), Profibrix (acquired by The Medicines Company), and Versartis (NASDAQ: VSAR). Dr De Rubertis received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva, and was then a postdoctoral scientist at the Whitehead Institute at MIT. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva. Dr De Rubertis was named by BioWorld as one of 28 “movers and shakers” predicted to shape the biotechnology industry over the next two decades.

Colin Orford

Colin Orford is ICON’s Vice President, Product Development, focusing on developing new models of drug development which range in scope from virtual development with small companies through to externalised development for large pharmaceutical companies. Dr Orford has 25 years of experience in the pharmaceutical sector gained at GSK, Novartis, Quintiles and Eisai. Over the course of Dr Orford’s career, he has been responsible for transitioning approximately 13 molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development. Dr Orford holds a P.D in microbial biochemistry and a PhD in endocrinology.

Tim de Gavre

Country Head UK
Sandoz

Schedule Overview

Date Number of Sessions First Session Starts Last Session Ends
Monday 5th 2018 10 01:30 PM 05:15 PM
Tuesday 6th 2018 16 09:00 AM 05:30 PM

Schedule Details

Day Time Session Details
Day 1 01:30 PM01:35 PM
Session

Opening Remarks from the Chair

Day 1 01:35 PM01:55 PM
Session

CEO Keynote Address/Interview

Day 1 01:55 PM02:45 PM
Session

Panel: Big Bang? Industrial Strategy - Creating a Successful Life Sciences Economy

Description

The UK has recently announced its sector deal for life sciences as part of its Industrial Strategy. Other countries
around the world are also making efforts to build their life sciences sectors in recognition of the industry’s hoped
for contribution to economic growth.

How effective will the UK’s life sciences strategy be in achieving its stated objectives? What difference will it make? Will it provide a ‘big bang’ for life sciences? Will it enable patients to achieve ‘the best standards of care’ and improve access?

Are healthcare systems ready and able to adopt and support the innovation which will emerge from these industrial strategy endeavours? Is the necessary alignment of payment, regulatory and development models in place to ensure success?

What does it take to create a truly competitive life science industry? How do you ‘go beyond the network’, for instance, to enable the innovation at the interface between industry academia and healthcare systems that creates new sources of data and the development of new drugs?

What is the role of clusters/ ecosystems, and how sustainable are all the new clusters/superclusters as growing numbers of countries competing in this space?

How important is life science to the economy, and it is money invested well?

Day 1 02:45 PM03:00 PM
Session

Keynote Interview

Day 1 03:00 PM03:15 PM
Session

Networking Coffee Break

Day 1 03:15 PM03:30 PM
Session

Presentation/Keynote Interview: The Future for Generics and Biosimilars

Day 1 03:30 PM04:20 PM
Session

China - A Disruptive Force in Life Sciences: Leader or Follower?

Description

China is stepping up its investment in life sciences, and is aiming to take a lead in key emerging areas to include genomics, gene editing and gene therapies. It is also now the second largest pharmaceutical in the world and is facing an epidemic of chronic and age related diseases. Recent moves by the industry regulator are paving the way for faster drug approvals and greater access for patients to advanced therapies. Meanwhile, China is embracing digital at a pace which eclipses the efforts in most other countries, and lacking the burden of legacy primary health care systems, is creating innovate new treatment and service models.

How is healthcare reform and the regulatory environment for life sciences in China evolving and what does it mean for pharma?

How is digital health evolving in China? What innovative approaches and strategies is China adopting to deal with ageing and management of chronic diseases? What are the implications of China’s approach to data as a public asset?

Will China be a leader or follower in drug development? What is the true level of innovation and ambition in China-the vision of China innovation 2020/2025?

What R&D strategies are Chinese life sciences company’s adopting, and what are the barriers to Chinese companies becoming fully fledged drug innovators? How might the emergence of Chinese innovation redefine the pathways for discovery and development of new drugs? What new innovations and approaches could we see emerging?

Will Chinese life sciences companies steal a lead by virtue of prowess in AI, computing, genomics and more lapse regulations with regard to advanced gene-based medicine?

Day 1 04:20 PM04:35 PM
Session

Keynote

Day 1 04:35 PM05:15 PM
Session

Investor Panel

Description

In this session our panel of leading investors – to include leading fund managers, corporate venture and charity investors – will share their views on the outlook for the industry and challenges ahead. The session will include views on the current round of deal making /M&A and consolidation and the implications for the industry. Will investors provide patient long-term capital to support the industry’s on-going transformation, including digital initiatives without proven IP and a framework for the valuation and monetisation of data, and potentially lower initial margins? Where do investors see opportunities emerging?

Day 1 05:15 PM05:15 PM
Session

Close of Day One

Day 2 09:00 AM09:05 AM
Session

Opening Remarks from the Chair

Day 2 09:05 AM09:25 AM
Session

FT Keynote Address/CEO Interview

Day 2 09:25 AM10:15 AM
Session

Panel: Big Data, Big Deal?

Description

What will it mean for the industry as payers continue to make advances in their ability to have continuous, real-time data enabling them not only to monitor and compare effectiveness of drugs, but to continuously assess the health of patients? How are payers strategies evolving in this space? In theory, this will lead to better patient care and better clinical trials, but there are many challenges remaining before the ‘data utopia’ becomes a reality, to include the lack of agreement on differening definitions of what constitutes value. How far are we from achieving the data utopia which underpins the many industry efforts to achieve greater productivity and patient focus with the help of technology? Does date have real value, and how do you get that value? Has data become too much, too complex and beyond the ability of life science and regulators to manage it? How much evidence is enough? Or too much? Where do we go from here? Enormous advances in gathering date and evidence, have been made but implementation has been challenging: Is the next stage of the digital health revolution a move to simplicity (e.g. the Uber health application)?

Day 2 10:15 AM11:00 AM
Session

Panel: Innovate Like a Start-Up: A New Future for R&D?

Description

In this session, our panel of leading Heads of R&D will share their views on the challenges facing R&D, and the strategies and approaches to reinvigorate drug development and research. Issues to be addressed could include:

New R&D models-prospects and challenges of public-private partnerships. Will we see more collaborations between government and industry to resolve the big research challenges which are beyond the capacity for big pharma to handle alone (e.g Alzheimer’s)?

How are R&D departments delivering on their ambition to do research more like entrepreneurial biotechs?

Virtual clinical trials-what do we need to do to make this a reality? Can clinical trials become treatment options?

The digital prescription for R&D – is big data slowing down drug development?

Digital + drugs and Digital therapeutics-what’s the verdict?

Is there a case for optimism in R&D?

Day 2 11:00 AM11:20 AM
Session

Networking Coffee Break

Day 2 11:20 AM12:00 PM
Session

Panel: Partnerships and Collaborations: What Works and Doesn't Work?

Description

The aim of this session is to provide visibility regarding what’s working and not working in the multiple types of partnering and collaborations being undertaken and explored by life sciences companies-from JV, to licensing to consortia and tie-ups increasingly with non-traditional industry players.

What’s working and not working? What have been the successes and challenges?

What are the trends in collaboration and partnering?

What novel types of collaborations might we see emerging?

Day 2 12:00 PM12:40 PM
Session

Panel: Patient-Centred Care and Patient - Centred Outcomes: Hope or Hype?

Description

Life science companies are working to place ‘serving the patient’ at the centre of their mission. The capture of patient focused data is becoming an essential part of drug approval and the reimbursement process and a focus on patient centricity helps build patient trust, can improve outcomes and adherence and help gain better acceptance by payers, providers, regulators and patients.

What are the strategies to support patient centricity on a full life-cycle basis? How is a focus on the patient impacting decision making? What does an all embracing, patient-centric life science company of the future look like? Are patient-centric approaches delivering on ROI?

How do you build a patient-centric corporate culture?

How are regulation and payer requirements regarding patient centricity and outcomes evolving?

Case study of a patient journey in one disease area: what were the experiences and learnings? How do patients define value and how do you measure it?

Day 2 12:40 PM02:00 PM
Session

Lunch

Day 2 02:00 PM02:40 PM
Session

New Industry Paradigms: Prevention - What is the Role for Pharma in Population Health Management?

Description

A focus on prevention and its potential for cost savings will become increasingly important if healthcare systems are to be able to afford the highly innovative, high-cost drugs which are coming our way. However, interventions focused on prevention are difficult to test and validate, and the economics are also fundamentally challenging. How can pharma play a role and excel in this space? Can the industry make money from prevention? What does it take to succeed in this space (e.g owning a consumer business)?

Day 2 02:40 PM03:20 PM
Session

Panel: From Treatment to Cure-Gene Therapy and Gene Editing- How will gene-based therapies transform medicine and healthcare?

Description

Long considered the holy grail of medicine, the era of genetic medicine is dawning at last. The recent FDA approval of a gene therapy marks the advent of a new era of cell and gene- based therapies that try to hack the body’s biology to tackle disease and hold out the promise of a paradigm shift from treatment to cure. Will gene therapies become the mainstay in treating and possibly curing our most devastating and intractable diseases?

How can pharma work with effectively with healthcare providers and patients to bring the benefits to patients?

Given the high price tag, what will be the impact on healthcare systems and how can they be paid for?

What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized, and their affordability and access is assured?

How do you value and put a price tag on potential cures?

What are the viable alternative pricing and financing models to ensure the full potential of these new treatments are realized and their affordability and access is assured?

Day 2 03:20 PM03:40 PM
Session

Networking Coffee Break

Day 2 03:40 PM04:30 PM
Session

Panel: Envisioning the Future of Diagnostics

Description

Some 70% of medical decisions, it is claimed are driven by diagnostics. As we enter the era of precision medicine, tailored therapeutics and AI, and as ever more rare diseases are investigated, diagnostics will continue to grow and the definition of what constitutes diagnostics will evolve.

A vision for the future of diagnostics

How will AI transform diagnostics?

The role of digital diagnostics-how robust are they? The challenges of regulating medical algorithms

Regulation and reimbursement challenges

Beyond oncology: prospects for expanding RX/DX/companion diagnostic to chronic disease and other disease states

Opportunities and challenges of early stage diagnostics

Next Frontiers in diagnostics: Immune system mapping and diagnostics: facial recognition diagnostics

The pitfalls of genetic testing-will we overwhelm the health system with the worried well?

Day 2 04:30 PM04:50 PM
Session

Presentation/ Panel New Horizons in Neuroscience/CNS

Description

What’s new in Neuroscience/CNS?

Day 2 04:50 PM05:25 PM
Session

Win Big, Lose Big? An Industry Call to Action

Description

Beyond R&D, how will tech and data disruption potentially transform other aspects of the business, to include commercial and supply chain? Will digital spell the end of the sales force and marketing as we know it? Will the industry become increasingly commoditised as these disruptions gradually chip away at all aspects of the business? Is the era of complacency regarding the disruptions set to reshape the industry now over? Will completely new business, skills and leadership models be needed? What is the key to surviving and thriving in this new era?

Day 2 05:25 PM05:30 PM
Session

Closing Remarks from the Chair

Day 2 05:30 PM05:30 PM
Session

End of conference

Ticket Price
Super Early Bird (ends 22 March) £1699.00
Early Bird (ends 28 May) £1799.00
Standard Summit Ticket £1899.00

Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.

You live in…

You are a…